One of the most significant health problems in our country relates directly to the consequences of pain. Estimates suggest that as many as 30 million Americans suffer from chronic pain which is resistant to medical treatment. One of the chronic abnormal pain states which is extremely difficult to treat is commonly referred to as """"""""neuropathic pain."""""""" Our understanding of this condition is limited, but has been increased in recent years by development of animal models in which injuries are made to peripheral nerves to produce signs which reflect some aspects of human neuropathic pain states. A striking result of these injuries is a substantial increase in the expression of spinal dynorphin. It is known that dynorphin may rapidly be degraded to des-Tyr fragments which do not interact with opioid receptors and that dynorphin can produce a significant number of effects which are non-opioid in nature. This proposal is aimed at testing the hypothesis that the spinal dynorphin is intimately involved in either the initiation or maintenance of nerve-injury related pain through non-opioid mechanisms. This hypothesis will be systematically tested by (a) measurement of whether and when dynorphin expression occurs in the spinal cord following specific nerve injuries; (b) determination of the functional consequences of spinal dynorphin and its role in maintenance of the post-injury state; (c)determination of the consequences of preemptive inhibition of dynorphin activity to evaluate its role in initiation of the nerve-injury consequences; (d) identification of a mechanism by which dynorphin may produce such pathological actions via interaction with a novel binding site on the NMDA receptor complex; and (e) direct evaluation of the effects of dynorphin on the viability of neurons. The present studies should reveal much about the role of dynorphin in post-injury processes in the spinal cord. It is expected that treatments that prevent the expression of spinal dynorphin or that block the actions of pathological levels of dynorphin at a specific site on the NMDA receptor complex should provide additional therapeutic benefit in the treatment of neuropathic pain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA011823-01
Application #
2606721
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Thomas, David D
Project Start
1998-04-01
Project End
2001-01-31
Budget Start
1998-04-01
Budget End
1999-01-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Arizona
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lee, Yeon Sun; Muthu, Dhanasekaran; Hall, Sara M et al. (2014) Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord. J Am Chem Soc 136:6608-16
Vera-Portocarrero, Louis P; Ossipov, Michael H; King, Tamara et al. (2008) Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 135:1369-78
Luo, Miaw-Chyi; Chen, Qingmin; Ossipov, Michael H et al. (2008) Spinal dynorphin and bradykinin receptors maintain inflammatory hyperalgesia. J Pain 9:1096-105
Lai, Josephine; Luo, Miaw-chyi; Chen, Qingmin et al. (2008) Pronociceptive actions of dynorphin via bradykinin receptors. Neurosci Lett 437:175-9
Shinoda, Katsumi; Hruby, Victor J; Porreca, Frank (2007) Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors. Neurosci Lett 411:143-6
King, Tamara; Vardanyan, Anna; Majuta, Lisa et al. (2007) Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 132:154-68
Vera-Portocarrero, Louis P; Yie, Jennifer X; Kowal, Justin et al. (2006) Descending facilitation from the rostral ventromedial medulla maintains visceral pain in rats with experimental pancreatitis. Gastroenterology 130:2155-64
Svensson, Camilla I; Hua, Xiao-Ying; Powell, Henry C et al. (2005) Prostaglandin E2 release evoked by intrathecal dynorphin is dependent on spinal p38 mitogen activated protein kinase. Neuropeptides 39:485-94
Koetzner, Lee; Hua, Xiao-Ying; Lai, Josephine et al. (2004) Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2. J Neurosci 24:1451-8
Gardell, L R; Ibrahim, M; Wang, R et al. (2004) Mouse strains that lack spinal dynorphin upregulation after peripheral nerve injury do not develop neuropathic pain. Neuroscience 123:43-52

Showing the most recent 10 out of 20 publications